Skip to main content
Top
Published in: Diabetologia 9/2021

01-09-2021 | Late Onset Autoimmune Diabetes in Adults | Article

HLA class I genes modulate disease risk and age at onset together with DR-DQ in Chinese patients with insulin-requiring type 1 diabetes

Authors: Ziyu Jiang, Wenqian Ren, Hua Liang, Jinhua Yan, Daizhi Yang, Sihui Luo, Xueying Zheng, Guo-Wang Lin, Yingxin Xian, Wen Xu, Bin Yao, Janelle A. Noble, Jin-Xin Bei, Leif Groop, Jianping Weng

Published in: Diabetologia | Issue 9/2021

Login to get access

Abstract

Aims/hypothesis

The study aimed to investigate the effects of HLA class I genes on susceptibility to type 1 diabetes with different onset ages, in addition to the well-established effects of HLA class II genes.

Methods

A total of 361 patients with type 1 diabetes (192 patients with onset <18 years and 169 patients with onset ≥18 years) and 500 healthy control participants from China were enrolled and genotyped for the HLA-A, -B, -C, -DQA1, -DQB1 and -DRB1 genes using next-generation sequencing.

Results

The susceptible DR3 (β = −0.09, p = 0.0009) and DR4-DQ8 (β = −0.13, p = 0.0059) haplotypes were negatively associated with onset age, while the protective DR11 (β = 0.21, p = 0.0314) and DR12 (β = 0.27, p < 0.0001) haplotypes were positively associated with onset age. After adjustment for linkage disequilibrium with DR-DQ haplotypes, A*11:01:01 was positively associated with onset age (β = 0.06, p = 0.0370), while the susceptible C*15:02:01 was negatively associated with onset age (β = −0.21, p = 0.0050). The unit for β was double square-root (fourth root) transformed years of change in onset age associated with per copy of the HLA haplotype/allele. In addition, B*46:01:01 was protective (OR 0.41, 0.46; pc [corrected for multiple comparisons] = 0.0044, 0.0040), whereas A*24:02:01 (OR 2.71, 2.25; pc = 0.0003, 0.0002) and B*54:01:01 (OR 3.96, 3.79; pc = 0.0018, 0.0004) were predisposing in both the <18 group and the ≥18 group compared with healthy control participants. In the context of DR4-DQ4, A*11:01:01 (61.29% vs 28.26%, pc = 0.0144) was increased while the predisposing A*24:02:01 (19.35% vs 47.83%, pc = 0.0403) was decreased in patients with onset ≥18 years when compared with patients with onset <18 years.

Conclusions/interpretation

In addition to DR-DQ haplotypes, novel HLA class I alleles were detected to play a role in susceptibility to type 1 diabetes with different onset ages, which could improve the understanding of disease heterogeneity and has implications for the design of future studies.

Graphical abstract

Appendix
Available only for authorised users
Literature
2.
go back to reference Zhu M, Xu K, Chen Y et al (2019) Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: based on a two-stage genome-wide association study. Diabetes Care 42(8):1414–1421. https://doi.org/10.2337/dc18-2023CrossRefPubMed Zhu M, Xu K, Chen Y et al (2019) Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D individuals: based on a two-stage genome-wide association study. Diabetes Care 42(8):1414–1421. https://​doi.​org/​10.​2337/​dc18-2023CrossRefPubMed
11.
14.
go back to reference Inshaw JRJ, Cutler AJ, Crouch DJM, Wicker LS, Todd JA (2020) Genetic variants predisposing Most strongly to type 1 diabetes diagnosed under age 7 years lie near candidate genes that function in the immune system and in pancreatic beta-cells. Diabetes Care 43(1):169–177. https://doi.org/10.2337/dc19-0803CrossRefPubMed Inshaw JRJ, Cutler AJ, Crouch DJM, Wicker LS, Todd JA (2020) Genetic variants predisposing Most strongly to type 1 diabetes diagnosed under age 7 years lie near candidate genes that function in the immune system and in pancreatic beta-cells. Diabetes Care 43(1):169–177. https://​doi.​org/​10.​2337/​dc19-0803CrossRefPubMed
26.
go back to reference Balke EM, Balti EV, Van der Auwera B et al (2018) Accelerated progression to type 1 diabetes in the presence of HLA-A*24 and -B*18 is restricted to multiple islet autoantibody-positive individuals with distinct HLA-DQ and autoantibody risk profiles. Diabetes Care 41(5):1076–1083. https://doi.org/10.2337/dc17-2462CrossRefPubMed Balke EM, Balti EV, Van der Auwera B et al (2018) Accelerated progression to type 1 diabetes in the presence of HLA-A*24 and -B*18 is restricted to multiple islet autoantibody-positive individuals with distinct HLA-DQ and autoantibody risk profiles. Diabetes Care 41(5):1076–1083. https://​doi.​org/​10.​2337/​dc17-2462CrossRefPubMed
29.
go back to reference Gorus FK, Balti EV, Messaaoui A et al (2017) Twenty-year progression rate to clinical onset according to autoantibody profile, age, and HLA-DQ genotype in a registry-based group of children and adults with a first-degree relative with type 1 diabetes. Diabetes Care 40(8):1065–1072. https://doi.org/10.2337/dc16-2228CrossRefPubMed Gorus FK, Balti EV, Messaaoui A et al (2017) Twenty-year progression rate to clinical onset according to autoantibody profile, age, and HLA-DQ genotype in a registry-based group of children and adults with a first-degree relative with type 1 diabetes. Diabetes Care 40(8):1065–1072. https://​doi.​org/​10.​2337/​dc16-2228CrossRefPubMed
38.
Metadata
Title
HLA class I genes modulate disease risk and age at onset together with DR-DQ in Chinese patients with insulin-requiring type 1 diabetes
Authors
Ziyu Jiang
Wenqian Ren
Hua Liang
Jinhua Yan
Daizhi Yang
Sihui Luo
Xueying Zheng
Guo-Wang Lin
Yingxin Xian
Wen Xu
Bin Yao
Janelle A. Noble
Jin-Xin Bei
Leif Groop
Jianping Weng
Publication date
01-09-2021
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-021-05476-6

Other articles of this Issue 9/2021

Diabetologia 9/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.